The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Tissue Regenix Group's Revenue for the
six
months ended in Jun. 2025 was €11.96 Mil. Tissue Regenix Group's average Accounts Receivable for the
six
months ended in Jun. 2025 was €3.53 Mil.
Hence, Tissue Regenix Group's Receivables Turnover for the
six
months ended in Jun. 2025 was 3.39.
Tissue Regenix Group (FRA:LSW) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Tissue Regenix Group Receivables Turnover Related Terms
Tissue Regenix Group Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Tissue Regenix Group's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:LSW vs VRTX, REGN, ALNY: Receivables Turnover Comparison
For the Biotechnology subindustry, Tissue Regenix Group's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tissue Regenix Group Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tissue Regenix Group's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Tissue Regenix Group's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tissue Regenix Group (FRA:LSW) has a Receivables Turnover of 3.39 as of Jun. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Tissue Regenix Group and its competitors.
Is Tissue Regenix Group's Receivables Turnover too high?
Tissue Regenix Group's current Receivables Turnover is 3.39. The Biotechnology industry median Receivables Turnover is 5.27. Tissue Regenix Group's value of 3.39 is 35.7% below this industry median. Overall, Tissue Regenix Group has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Tissue Regenix Group's Receivables Turnover compare to VRTX and REGN?
Tissue Regenix Group's Receivables Turnover of 3.39 can be compared against companies in the Biotechnology industry. The industry median Receivables Turnover is 5.27. Tissue Regenix Group's value of 3.39 is 35.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.27, based on 839 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tissue Regenix Group's current Receivables Turnover of 3.39 is 35.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Tissue Regenix Group and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tissue Regenix Group's current Receivables Turnover is 3.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tissue Regenix Group stock overvalued right now?
Tissue Regenix Group (FRA:LSW) has a current Receivables Turnover of 3.39. The stock's GF Value™ is €0.84, compared to a current price of €0.07 — trading 91.7% below its estimated fair value. The current Receivables Turnover is 3.39 and 35.7% below the Biotechnology industry median of 5.27. Tissue Regenix Group's overall GF Score™ is 10/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Tissue Regenix Group (FRA:LSW), the current Receivables Turnover is 3.39 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tissue Regenix Group (FRA:LSW) Overvalued in 2026?
Based on GuruFocus' analysis, Tissue Regenix Group stock appears to be undervalued.
The current stock price of €0.07 is trading 91.7% below its estimated GF Value™ of €0.84.
Key valuation signals for FRA:LSW:
Receivables Turnover: 3.39
GF Value™: €0.84 vs. price of €0.07 (91.7% below fair value)
Industry Position: 35.7% below the Biotechnology median
No single metric tells the full story. See the FRA:LSW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tissue Regenix Group PLC is a pioneering medical technology company engaged in the development of regenerative products. The company incorporates dCELL and BioRinse technology, which helps to address complex and varying clinical needs. Its product portfolio includes Biosurgery, Orthopaedics, and Dental. The company has operations around the world, with special emphasis in the United States.
10GF Score
Get the complete analysis for FRA:LSW
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LSW has been successfully added to your 
